Description: Kelly CRISPR & Gene Editing Technology ETF is an exchange traded fund launched and managed by Kelly Strategic Management, LLC. The fund is co-managed by Penserra Capital Management, LLC. It invests in public equity markets of global developed markets region. The fund invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences, biotechnology, gene research and development, rDNA pharmaceuticals, CRISPR and gene editing technology, gene editing development solutions and gene editing sequencing solutions sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track the performance of the Strategic CRISPR & Gene Editing Technology Index, by using full replication technique. Kelly CRISPR & Gene Editing Technology ETF is domiciled in the United States.
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
Category: Health
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock US | 84.63 | 0.00 | 84.63 |
| Stock non-US | 15.18 | 0.00 | 15.18 |
| Cash | 0.19 | 0.00 | 0.19 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 100.00 | 99.57 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| North America | 84.79 | 92.60 |
| Europe Developed | 15.21 | 4.28 |
| Japan | 0.00 | 0.54 |
| Australasia | 0.00 | 0.11 |
| Asia Emerging | 0.00 | 0.82 |
| United Kingdom | 0.00 | 1.65 |
| Africa/Middle East | 0.00 | 0.02 |